Paediatric regulations earn companies/cost Europe billions, says generics industry
This article was originally published in Scrip
Executive Summary
Originator companies complain that the EU Paediatric Regulation offers heavy burden for scant reward, but number crunching by the British Generic Medicines Association reveals that firms in the UK have raked in at least £379.7 million thanks to the six month supplementary protection certificate extensions awarded under regulations.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.